Cagrilintide

🔹 What is Cagrilintide?

Class: Synthetic peptide—long-acting amylin analogue, designed to mimic the hormone amylin, which is co-secreted with insulin in the pancreas. Mechanism: Binds amylin receptors to slow gastric emptying, suppress appetite, and modulate postprandial glucagon release. Works synergistically with GLP-1 pathways to improve satiety and aid in body weight regulation. Primary focus: Appetite regulation, weight loss, improved glycemic control, fat mass reduction, and metabolic support. 🔹 Oral Dosage (least common) Range studied/used in research: Oral bioavailability is extremely low; not used orally. Typical protocol: No oral standard; all human and animal research uses injectable subcutaneous formulations. Notes: Subcutaneous injection is the preferred and effective delivery route. Oral or other non-injectable forms are not practical.

---

🔹 Injectable / Subcutaneous Dosage (most common) Range: Research and clinical trials typically use 0.3–4.5 mg per week subcutaneously, depending on titration schedules and combination therapies (e.g., with semaglutide). Frequency: Once weekly; long-acting formulation allows sustained receptor activation and reduced injection frequency. Rationale: Slow-release properties improve tolerability and steady appetite suppression, avoiding peaks that could cause nausea or other side effects.

---

🔹 Cycle Length Common cycle length: Typically studied in 12–24 week clinical trials for weight management. Off-cycle: Not formally established; discontinuation is based on treatment goals or clinical evaluation. Note: Cycle duration and dosing adjustments are often guided by weight-loss targets, tolerability, and combination with GLP-1 analogues.

---

🔹 Optimal Dosing Window Injectable / Subcutaneous: Once weekly, timing flexible. Many users choose morning or midday to align with active hours and maximize appetite control. Avoid late evening if prone to nausea or digestive sensitivity.

---

✅ Educational Integration Example (injectable) Example protocol: 2 mg subcutaneous injection once weekly for 12 weeks, titrating from lower starting dose (e.g., 0.3 mg) to reduce gastrointestinal side effects. Pair with: Calorie-conscious diet, adequate protein, exercise, and hydration to maximize weight-loss and metabolic benefits.

---

🔹 Stacking Strategy (Educational) Since Cagrilintide targets appetite suppression, gastric emptying, and weight management, stacks can focus on synergistic metabolic and satiety support: 🔸 Metabolic & Fat Loss Support

• GLP-1 analogues (Semaglutide, Tirzepatide, or Retatrutide): Complement amylin signaling for enhanced weight loss and glycemic control.
• AOD-9604: May enhance fat loss through GH-fragment mediated lipolysis.

🔸 Recovery & Systemic Health

• L-Carnitine / MIC blends: Supports mitochondrial fat oxidation and energy metabolism.
• Exercise & resistance training: Preserves lean mass during caloric deficit.

🔸 Longevity / Metabolic Optimization

• NAD⁺ precursors (NMN/NR): Supports metabolic resilience and mitochondrial energy.
• Omega-3 fatty acids: Reduce inflammation and support cardiovascular health during weight management.

Disclaimer: Do not rely on any dosing information provided, this is for educational and research only. Always double and triple check alternative references for education. Please consult with healthcare provider for your specific dosing and protocol if applicable.